Case Study Undergraduate 644 words

Eli Lilly's Ranbaxy Joint Venture Buyout Decision in India

~4 min read

Abstract

This paper examines the strategic decision facing Eli Lilly regarding its joint venture in India with Ranbaxy Laboratories. As Ranbaxy prepares to exit the partnership, Lilly must choose between buying out the share outright or bringing in a new Indian partner. The paper evaluates the Indian pharmaceutical market's growth potential, including expanding patent protections, rising sales and profits within the subsidiary, and opportunities in clinical drug testing. It also considers risks related to distribution networks, ethical culture, and brand identity before recommending that Lilly purchase Ranbaxy's stake and operate the venture as a wholly-owned subsidiary.

📝 How to Write This Type of Paper Writing guide — click to expand

▼

What makes this paper effective

Grounds its recommendation in concrete financial evidence — citing 56.5% sales growth and 103% profit growth — rather than relying solely on qualitative reasoning.
Balances the appeal of a new Indian partner against specific risks (distribution disruption, cultural misalignment) before arriving at a clear conclusion.
Acknowledges uncertainty honestly, noting that the asking price for Ranbaxy's share is unknown and that Lilly must establish a negotiating ceiling.

Key academic technique demonstrated

The paper demonstrates applied strategic analysis by systematically weighing internal capabilities (brand equity, established culture) against external market conditions (patent reform, middle-class growth) before committing to a single recommendation. This mirrors a classic business case framework: situation assessment, option evaluation, and justified recommendation.

Structure breakdown

The paper opens with a direct thesis statement, then provides market context and quantitative performance data before examining the pros and cons of each strategic option. It closes with a dedicated recommendation section that revisits key evidence and concedes the remaining risks. The structure is linear and argument-driven, making it suitable as a short business case study or executive memo.

Introduction and Strategic Context

Eli Lilly should buy out Ranbaxy's share of the joint venture. The company has grown and now has the ability to stand on its own. The Indian pharmaceutical market has tremendous potential, but bringing in another Indian partner is too risky and could compromise the company's ability to unlock that potential.

The situation Lilly faces in India is whether to buy out partner Ranbaxy or to take on a new partner. The joint venture has been a success for Lilly, allowing it to enter the Indian market profitably. Ranbaxy wants to leave the joint venture, and Lilly must determine whether it can run the venture as a wholly-owned subsidiary or whether it should take on another Indian partner.

Indian Market Conditions and Growth

The Indian market presents favorable conditions for continued investment. With patent protection coming on stream, margins in India should increase, potentially allowing Eli Lilly to bring some of its patent-protected drugs to market — something it has not wanted to do in the past. The subsidiary has seen strong growth in recent years, with sales rising 56.5% and profits increasing 103% over the same two-year span. The balance sheet has become somewhat weaker, however, with liquidity declining over that period.

There are a number of opportunities within the Indian market. These include a growing population and an expanding middle class. The country also has potential as a location for clinical drug testing, provided that standards can be met to make trials conducted in India applicable to Western regulatory approval processes. This could represent significant cost savings for Lilly.

Opportunities and Risks in the Indian Market

It is worth noting, however, that despite the high potential of emerging markets, foreign sales as a percentage of Lilly's total revenues have been declining. Its core business at present remains centered on the U.S. market.

2 Locked Sections · 275 words remaining

Evaluating the Partnership Options · 130 words

"Distribution and cultural risks of replacing Ranbaxy"

Recommendation and Conclusion · 145 words

"Buy out Ranbaxy and operate as wholly-owned subsidiary"

You’re 45% through this paper. Sign up to read the remaining 2 sections.

130,000+ paper examples AI writing assistant Citation generator Cancel anytime

Key Concepts in This Paper

Joint Venture Buyout Indian Pharma Market Patent Protection Distribution Network Brand Equity Emerging Markets Cultural Integration Market Entry Strategy Wholly-Owned Subsidiary Strategic Partnership